Get More Information on Weight Loss Drugs Market- Request Sample Report
The Weight Loss Drugs Market Size was valued at USD 1.92 Billion in 2023 and is expected to reach USD 45.35 Billion by 2032 and grow at a CAGR of 43.73% over the forecast period 2024-2032.
The growing obesity rates are the main factor driving the weight loss drugs market, largely boosting its growth. As of 2022, more than 650 million adults around the world were obese and since 1975 global prevalence has nearly tripled according to the World Health Organization (WHO) According to data from the Centers for Disease Control and Prevention (CDC), 42.4 percent of American adults are affected by obesity, highlighting a critical need for efficacious weight management solutions that work fast. Hence the increase in demand for weight loss medications to assist with this rising obesity rate as people and healthcare systems struggle against this epidemic.
Obesity prevention and treatment are a growing global priority that will drive sales of weight loss drugs by governments and health organizations. Programs such as the U.S. National Institutes of Health (NIH) Obesity Research Strategic Plan and similar efforts in other countries, all underscore that pharmacological support or supplementation will have to be a vital part of strategies for fighting this scourge. The rise in obesity is estimated to drive the Global Weight Loss Drugs Market. Obesity prevalence across millions globally has led to an escalation in demand for efficacious weight loss medications, fostering the growth of the global weight loss drugs market.
MARKET DYNAMICS:
KEY DRIVERS:
The Growing Prevalence of Obesity is Responsible for the Increasing Demand for Weight Loss Drugs Propelling Market Growth.
Increased Focus on Preventive Healthcare and Weight Management is Boosting the Weight Loss Drugs Market Growth.
RESTRAINTS:
Stringent Regulatory Scenario is Hindering Weight Loss Drugs Market Growth.
High Cost of Weight Loss Drugs Can Limit the Growth of Weight Loss Drugs.
OPPORTUNITY:
Rising Research and Development Activities for Novel Drug Development are Offering a Lucrative Growth Opportunity for Weight Loss Drugs Market.
Funding and Support for Obesity Research and Public Health Campaigns are Responsible for the Market Growth During Upcoming Years.
By Drug Type
The prescription drugs segment accounted for the major share in 2023 which was 56%, as they are more efficacious and provide specific treatment options targeted to severe obesity. As the National Institutes of Health data indicates more than 42% of American adults qualify as obese - a level at which over-the-counter (OTC) solutions may be ineffective and prescription interventions are often needed to treat. But many times, prescription weight loss medication, like GLP-1 receptor agonists (Semaglutide [Wegovy]) and combination drugs (Phentermine-Topiramate) are necessary to penetrate through this barrier of complexity by providing the scale-inducing results that have eluded those impacted similarly dealing with obesity-related health conditions regardless of lifestyle changes. They are thoroughly tested in clinical trials and endure a process of regulatory oversight, such that the U.S. Food and Drug Administration (FDA) has only given its approval to these medications after it is satisfied by data on their safety and effectiveness.
OTC drugs, on the other hand, are easily available and convenient but they generally have weaker weight loss impacts than dietary supplements and often fall into the more moderate weight management category. The prescription drugs market share is based on large-scale research, medical surveillance, and coverage by insurance which makes the category a popular choice in professional treatment for severe obesity, ultimately driving the growth of weight loss drugs overall.
By Mechanism of Action
Appetite suppressants are the largest mechanism of action in weight loss drugs holding 52% in 2023 because they have a direct and immediate effect on lowering food consumption. The appetite suppressants operate to manipulate the brain's satiety signals thus discouraging the gorging instincts and then helping slash those mandatory intakes of calories. Although the mechanism targets just one of the core difficulties in weight control - modifying hunger. For example, appetite is greatly decreased by drugs such as Phentermine and GLP-1 receptor agonists (such as Semaglutide - Wegovy) resulting in very good results for the ones looking to lose a considerable amount of weight. As appetite suppressants have a proven record of workability and are used globally, this is why they make up a significant part of the weight loss drugs market worldwide. The availability and also results of these medicines make them wanted by people looking for easy therapies.
By comparison fat absorption inhibitors and combination drugs are effective in a different part of weight management, overall, they make up for smaller market segments. Fat absorption inhibitors prevent the intestines from absorbing dietary fats, and combination drugs create multiple mechanisms of action but are less widely used. Based on the mechanism of action, appetite suppressants are the largest segment by far due to their direct effect on hunger and proven efficacy in the weight loss drugs market.
Need any customization research on Weight Loss Drugs Market - Enquiry Now
REGIONAL ANALYSIS:
North America was the largest region in the weight loss drugs market which had 44% of the market share in 2023 due to its high obesity population and presence of well-established healthcare infrastructure. For instance, The United States has one of the highest rates of obesity in the world: nearly 42.4% of adults are struggling with obesity according to CDC (Centers for Disease Control and Prevention) data. Owing to such prevalence, demand for weight loss drugs - prescription and over-the-counter is robust. The area is served by an advanced medical care system, which enables considerable availability of these drugs. Moreover, the rise in demand from obesity patients and North America's well-established pharmaceutical market with a large number of organized players taking to retail as well as online pharmacy formats creating access points for weight-loss drugs are further driving the growth factors for global OTC availability. Supportive legislation by regulatory bodies such as the U.S. Food and Drug Administration (FDA) for approving and regulating these medications is aiding in market expansion. While government initiatives and public health campaigns in the region also stress weight management, it is otherwise to continue boosting weight loss drug use. Together, these factors make North America the dominant region in the global weight loss drugs market.
The key market players include Roche Holding AG, Novo Nordisk A/S, GlaxoSmithKline plc, Eisai Co., Ltd., Currax Pharmaceuticals LLC, VIVUS, Inc., Pfizer Inc., Johnson & Johnson, AstraZeneca, Eli Lilly and Company & other players.
RECENT DEVELOPMENTS
Some prominent names in the weight loss drug market are ramping up efforts to invent novel substances that would be more effective for patients. It Includes One such example (R-Zepbound IP ZEPET) of a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-such as peptide-1 (GLP-1) receptor agonist for the treatment of Fatty liver disease. The US Food and Drug Administration later approved in November 2023 the injectable form of tripeptide (Zepbound) by Eli Lilly and Company, an American pharmaceutical company, for chronic weight management among adults with overweight or obesity who have at least one associated comorbid condition. Zepbound is one of the first and only FDA-approved obesity treatments that engage both GIP and GLP-1 receptors, implying a strong commercial runway.
Roche Holding AG, a Switzerland-based healthcare company also acquired Carmot Therapeutics Inc. in December 2023 for $2.7 billion as well This strategic purchase afforded Roche two obesity prospects, possessing a phase 2 injectable as well being lined up for phase 1 clinical trials about another pill form. The purchase was designed to bolster Roche's presence in the hot and crowded obesity drug field. About Carmot Therapeutics Inc. Carmot is a US clinical-stage biotechnology company focused on the discovery and development of disease-modifying drugs for obesity and type 2 diabetes.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 1.92 Billion |
| Market Size by 2032 | US$ 45.35 Billion |
| CAGR | CAGR of 43.73% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | •By Drug Type (Prescription Drugs & Over-the-Counter Drugs (OTC)) •By Mechanism of Action (Appetite Suppressants, Fat Absorption Inhibitors & Combination Drugs) •By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Roche Holding AG, Novo Nordisk A/S, GlaxoSmithKline plc, Eisai Co., Ltd., Currax Pharmaceuticals LLC, VIVUS, Inc.,Pfizer Inc., Johnson & Johnson, AstraZeneca, Eli Lilly and Company & other players |
| Key Drivers | •The Growing Prevalence of Obesity is Responsible for the Increasing Demand for Weight Loss Drugs Propelling Market Growth. •Increased Focus on Preventive Healthcare and Weight Management is Boosting the Weight Loss Drugs Market Growth. |
| RESTRAINTS | •Stringent Regulatory Scenario is Hindering Weight Loss Drugs Market Growth. •High Cost of Weight Loss Drugs Can Limit the Growth of Weight Loss Drugs. |
Ans: The Weight Loss Drugs Market was valued at USD 1.92 Billion in 2023.
Ans: The expected CAGR of the Global Weight Loss Drugs Market during the forecast period is 43.73%.
Ans Prescription Drug Type will increase in the Weight Loss Drugs Market in 2023.
Ans: Factors such as the stringent regulatory scenario as well as the high cost of weight loss drugs can limit the growth of Weight Loss Drugs.
Ans: The U.S. led the Weight Loss Drugs in the North American region with the highest revenue share in 2023.
TABLE OF CONTENTS
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Industry Flowchart
3. Research Methodology
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
5. Porter’s 5 Forces Model
6. Pest Analysis
7. Weight Loss Drugs Market Segmentation, By Drug Type
7.1 Introduction
7.2 Prescription Drugs
7.3 Over-the-Counter Drugs (OTC)
8. Weight Loss Drugs Market Segmentation, By Mechanism of Action
8.1 Introduction
8.2 Appetite Suppressants
8.3 Fat Absorption Inhibitors
8.4 Combination Drugs
9. Weight Loss Drugs Market Segmentation, By Distribution Channel
9.1 Introduction
9.2 Hospital Pharmacies
9.3 Retail Pharmacies
9.4 Online Pharmacies
10. Regional Analysis
10.1 Introduction
10.2 North America
10.2.1 Trend Analysis
10.2.2 North America Weight Loss Drugs Market by Country
10.2.3 North America Weight Loss Drugs Market By Drug Type
10.2.4 North America Weight Loss Drugs Market By Mechanism of Action
10.2.5 North America Weight Loss Drugs Market By Distribution Channel
10.2.6 USA
10.2.6.1 USA Weight Loss Drugs Market By Drug Type
10.2.6.2 USA Weight Loss Drugs Market By Mechanism of Action
10.2.6.3 USA Weight Loss Drugs Market By Distribution Channel
10.2.7 Canada
10.2.7.1 Canada Weight Loss Drugs Market By Drug Type
10.2.7.2 Canada Weight Loss Drugs Market By Mechanism of Action
10.2.7.3 Canada Weight Loss Drugs Market By Distribution Channel
10.2.8 Mexico
10.2.8.1 Mexico Weight Loss Drugs Market By Drug Type
10.2.8.2 Mexico Weight Loss Drugs Market By Mechanism of Action
10.2.8.3 Mexico Weight Loss Drugs Market By Distribution Channel
10.3 Europe
10.3.1 Trend Analysis
10.3.2 Eastern Europe
10.3.2.1 Eastern Europe Weight Loss Drugs Market by Country
10.3.2.2 Eastern Europe Weight Loss Drugs Market By Drug Type
10.3.2.3 Eastern Europe Weight Loss Drugs Market By Mechanism of Action
10.3.2.4 Eastern Europe Weight Loss Drugs Market By Distribution Channel
10.3.2.5 Poland
10.3.2.5.1 Poland Weight Loss Drugs Market By Drug Type
10.3.2.5.2 Poland Weight Loss Drugs Market By Mechanism of Action
10.3.2.5.3 Poland Weight Loss Drugs Market By Distribution Channel
10.3.2.6 Romania
10.3.2.6.1 Romania Weight Loss Drugs Market By Drug Type
10.3.2.6.2 Romania Weight Loss Drugs Market By Mechanism of Action
10.3.2.6.4 Romania Weight Loss Drugs Market By Distribution Channel
10.3.2.7 Hungary
10.3.2.7.1 Hungary Weight Loss Drugs Market By Drug Type
10.3.2.7.2 Hungary Weight Loss Drugs Market By Mechanism of Action
10.3.2.7.3 Hungary Weight Loss Drugs Market By Distribution Channel
10.3.2.8 Turkey
10.3.2.8.1 Turkey Weight Loss Drugs Market By Drug Type
10.3.2.8.2 Turkey Weight Loss Drugs Market By Mechanism of Action
10.3.2.8.3 Turkey Weight Loss Drugs Market By Distribution Channel
10.3.2.9 Rest of Eastern Europe
10.3.2.9.1 Rest of Eastern Europe Weight Loss Drugs Market By Drug Type
10.3.2.9.2 Rest of Eastern Europe Weight Loss Drugs Market By Mechanism of Action
10.3.2.9.3 Rest of Eastern Europe Weight Loss Drugs Market By Distribution Channel
10.3.3 Western Europe
10.3.3.1 Western Europe Weight Loss Drugs Market by Country
10.3.3.2 Western Europe Weight Loss Drugs Market By Drug Type
10.3.3.3 Western Europe Weight Loss Drugs Market By Mechanism of Action
10.3.3.4 Western Europe Weight Loss Drugs Market By Distribution Channel
10.3.3.5 Germany
10.3.3.5.1 Germany Weight Loss Drugs Market By Drug Type
10.3.3.5.2 Germany Weight Loss Drugs Market By Mechanism of Action
10.3.3.5.3 Germany Weight Loss Drugs Market By Distribution Channel
10.3.3.6 France
10.3.3.6.1 France Weight Loss Drugs Market By Drug Type
10.3.3.6.2 France Weight Loss Drugs Market By Mechanism of Action
10.3.3.6.3 France Weight Loss Drugs Market By Distribution Channel
10.3.3.7 UK
10.3.3.7.1 UK Weight Loss Drugs Market By Drug Type
10.3.3.7.2 UK Weight Loss Drugs Market By Mechanism of Action
10.3.3.7.3 UK Weight Loss Drugs Market By Distribution Channel
10.3.3.8 Italy
10.3.3.8.1 Italy Weight Loss Drugs Market By Drug Type
10.3.3.8.2 Italy Weight Loss Drugs Market By Mechanism of Action
10.3.3.8.3 Italy Weight Loss Drugs Market By Distribution Channel
10.3.3.9 Spain
10.3.3.9.1 Spain Weight Loss Drugs Market By Drug Type
10.3.3.9.2 Spain Weight Loss Drugs Market By Mechanism of Action
10.3.3.9.3 Spain Weight Loss Drugs Market By Distribution Channel
10.3.3.10 Netherlands
10.3.3.10.1 Netherlands Weight Loss Drugs Market By Drug Type
10.3.3.10.2 Netherlands Weight Loss Drugs Market By Mechanism of Action
10.3.3.10.3 Netherlands Weight Loss Drugs Market By Distribution Channel
10.3.3.11 Switzerland
10.3.3.11.1 Switzerland Weight Loss Drugs Market By Drug Type
10.3.3.11.2 Switzerland Weight Loss Drugs Market By Mechanism of Action
10.3.3.11.3 Switzerland Weight Loss Drugs Market By Distribution Channel
10.3.3.12 Austria
10.3.3.12.1 Austria Weight Loss Drugs Market By Drug Type
10.3.3.12.2 Austria Weight Loss Drugs Market By Mechanism of Action
10.3.3.12.3 Austria Weight Loss Drugs Market By Distribution Channel
10.3.3.13 Rest of Western Europe
10.3.3.13.1 Rest of Western Europe Weight Loss Drugs Market By Drug Type
10.3.3.13.2 Rest of Western Europe Weight Loss Drugs Market By Mechanism of Action
10.3.3.13.3 Rest of Western Europe Weight Loss Drugs Market By Distribution Channel
10.4 Asia-Pacific
10.4.1 Trend Analysis
10.4.2 Asia-Pacific Weight Loss Drugs Market by Country
10.4.3 Asia-Pacific Weight Loss Drugs Market By Drug Type
10.4.4 Asia-Pacific Weight Loss Drugs Market By Mechanism of Action
10.4.5 Asia-Pacific Weight Loss Drugs Market By Distribution Channel
10.4.6 China
10.4.6.1 China Weight Loss Drugs Market By Drug Type
10.4.6.2 China Weight Loss Drugs Market By Mechanism of Action
10.4.6.3 China Weight Loss Drugs Market By Distribution Channel
10.4.7 India
10.4.7.1 India Weight Loss Drugs Market By Drug Type
10.4.7.2 India Weight Loss Drugs Market By Mechanism of Action
10.4.7.3 India Weight Loss Drugs Market By Distribution Channel
10.4.8 Japan
10.4.8.1 Japan Weight Loss Drugs Market By Drug Type
10.4.8.2 Japan Weight Loss Drugs Market By Mechanism of Action
10.4.8.3 Japan Weight Loss Drugs Market By Distribution Channel
10.4.9 South Korea
10.4.9.1 South Korea Weight Loss Drugs Market By Drug Type
10.4.9.2 South Korea Weight Loss Drugs Market By Mechanism of Action
10.4.9.3 South Korea Weight Loss Drugs Market By Distribution Channel
10.4.10 Vietnam
10.4.10.1 Vietnam Weight Loss Drugs Market By Drug Type
10.4.10.2 Vietnam Weight Loss Drugs Market By Mechanism of Action
10.4.10.3 Vietnam Weight Loss Drugs Market By Distribution Channel
10.4.11 Singapore
10.4.11.1 Singapore Weight Loss Drugs Market By Drug Type
10.4.11.2 Singapore Weight Loss Drugs Market By Mechanism of Action
10.4.11.3 Singapore Weight Loss Drugs Market By Distribution Channel
10.4.12 Australia
10.4.12.1 Australia Weight Loss Drugs Market By Drug Type
10.4.12.2 Australia Weight Loss Drugs Market By Mechanism of Action
10.4.12.3 Australia Weight Loss Drugs Market By Distribution Channel
10.4.13 Rest of Asia-Pacific
10.4.13.1 Rest of Asia-Pacific Weight Loss Drugs Market By Drug Type
10.4.13.2 Rest of Asia-Pacific Weight Loss Drugs Market By Mechanism of Action
10.4.13.3 Rest of Asia-Pacific Weight Loss Drugs Market By Distribution Channel
10.5 Middle East & Africa
10.5.1 Trend Analysis
10.5.2 Middle East
10.5.2.1 Middle East Weight Loss Drugs Market by Country
10.5.2.2 Middle East Weight Loss Drugs Market By Drug Type
10.5.2.3 Middle East Weight Loss Drugs Market By Mechanism of Action
10.5.2.4 Middle East Weight Loss Drugs Market By Distribution Channel
10.5.2.5 UAE
10.5.2.5.1 UAE Weight Loss Drugs Market By Drug Type
10.5.2.5.2 UAE Weight Loss Drugs Market By Mechanism of Action
10.5.2.5.3 UAE Weight Loss Drugs Market By Distribution Channel
10.5.2.6 Egypt
10.5.2.6.1 Egypt Weight Loss Drugs Market By Drug Type
10.5.2.6.2 Egypt Weight Loss Drugs Market By Mechanism of Action
10.5.2.6.3 Egypt Weight Loss Drugs Market By Distribution Channel
10.5.2.7 Saudi Arabia
10.5.2.7.1 Saudi Arabia Weight Loss Drugs Market By Drug Type
10.5.2.7.2 Saudi Arabia Weight Loss Drugs Market By Mechanism of Action
10.5.2.7.3 Saudi Arabia Weight Loss Drugs Market By Distribution Channel
10.5.2.8 Qatar
10.5.2.8.1 Qatar Weight Loss Drugs Market By Drug Type
10.5.2.8.2 Qatar Weight Loss Drugs Market By Mechanism of Action
10.5.2.8.3 Qatar Weight Loss Drugs Market By Distribution Channel
10.5.2.9 Rest of Middle East
10.5.2.9.1 Rest of Middle East Weight Loss Drugs Market By Drug Type
10.5.2.9.2 Rest of Middle East Weight Loss Drugs Market By Mechanism of Action
10.5.2.9.3 Rest of Middle East Weight Loss Drugs Market By Distribution Channel
10.5.3 Africa
10.5.3.1 Africa Weight Loss Drugs Market by Country
10.5.3.2 Africa Weight Loss Drugs Market By Drug Type
10.5.3.3 Africa Weight Loss Drugs Market By Mechanism of Action
10.5.3.4 Africa Weight Loss Drugs Market By Distribution Channel
10.5.3.5 Nigeria
10.5.3.5.1 Nigeria Weight Loss Drugs Market By Drug Type
10.5.3.5.2 Nigeria Weight Loss Drugs Market By Mechanism of Action
10.5.3.5.3 Nigeria Weight Loss Drugs Market By Distribution Channel
10.5.3.6 South Africa
10.5.3.6.1 South Africa Weight Loss Drugs Market By Drug Type
10.5.3.6.2 South Africa Weight Loss Drugs Market By Mechanism of Action
10.5.3.6.3 South Africa Weight Loss Drugs Market By Distribution Channel
10.5.3.7 Rest of Africa
10.5.3.7.1 Rest of Africa Weight Loss Drugs Market By Drug Type
10.5.3.7.2 Rest of Africa Weight Loss Drugs Market By Mechanism of Action
10.5.3.7.3 Rest of Africa Weight Loss Drugs Market By Distribution Channel
10.6 Latin America
10.6.1 Trend Analysis
10.6.2 Latin America Weight Loss Drugs Market by country
10.6.3 Latin America Weight Loss Drugs Market By Drug Type
10.6.4 Latin America Weight Loss Drugs Market By Mechanism of Action
10.6.5 Latin America Weight Loss Drugs Market By Distribution Channel
10.6.6 Brazil
10.6.6.1 Brazil Weight Loss Drugs Market By Drug Type
10.6.6.2 Brazil Weight Loss Drugs Market By Mechanism of Action
10.6.6.3 Brazil Weight Loss Drugs Market By Distribution Channel
10.6.7 Argentina
10.6.7.1 Argentina Weight Loss Drugs Market By Drug Type
10.6.7.2 Argentina Weight Loss Drugs Market By Mechanism of Action
10.6.7.3 Argentina Weight Loss Drugs Market By Distribution Channel
10.6.8 Colombia
10.6.8.1 Colombia Weight Loss Drugs Market By Drug Type
10.6.8.2 Colombia Weight Loss Drugs Market By Mechanism of Action
10.6.8.3 Colombia Weight Loss Drugs Market By Distribution Channel
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Weight Loss Drugs Market By Drug Type
10.6.9.2 Rest of Latin America Weight Loss Drugs Market By Mechanism of Action
10.6.9.3 Rest of Latin America Weight Loss Drugs Market By Distribution Channel
11. Company Profiles
11.1 Roche Holding AG
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Mechanism of Actions Offered
11.1.4 The SNS View
11.2 Novo Nordisk A/S
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Mechanism of Actions Offered
11.2.4 The SNS View
11.3 GlaxoSmithKline plc
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Mechanism of Actions Offered
11.3.4 The SNS View
11.4 Eisai Co., Ltd.
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Mechanism of Actions Offered
11.4.4 The SNS View
11.5 Currax Pharmaceuticals LLC
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Mechanism of Actions Offered
11.5.4 The SNS View
11.6 VIVUS, Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Mechanism of Actions Offered
11.6.4 The SNS View
11.7 Pfizer Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Mechanism of Actions Offered
11.7.4 The SNS View
11.8 Johnson & Johnson
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Mechanism of Actions Offered
11.8.4 The SNS View
11.9 AstraZeneca
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Mechanism of Actions Offered
11.9.4 The SNS View
11.10 Eli Lilly and Company
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Mechanism of Actions Offered
11.10.4 The SNS View
12. Competitive Landscape
12.1 Competitive Benchmarking
12.2 Market Share Analysis
12.3 Recent Developments
12.3.1 Industry News
12.3.2 Company News
12.3.3 Mergers & Acquisitions
13. Use Case and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Drug Type
Prescription Drugs
Over-the-counter drugs (OTC)
By Mechanism of Action
Appetite Suppressants
Fat Absorption Inhibitors
Combination Drugs
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Single-Use Bioreactors Market Size was valued at USD 3872.40 million in 2023 and is expected to reach USD 13784.83 million by 2031 and grow at a CAGR of 17.2% over the forecast period 2024-2031.
The Healthcare Consulting Services Market Size was valued at USD 26.35 Bn in 2023, & will reach USD 59.75 Bn by 2032, & grow at a CAGR of 9.54% by 2024-2032.
The Burn Care Market size was valued at USD 3.10 Billion in 2023. It is estimated to reach USD 5.70 Billion by 2032, growing at a CAGR of 7.02% during 2024-2032.
The Medical Device Connectivity Market Size was valued at USD 2.45 billion in 2023, and is expected to reach USD 16.21 billion by 2031 and grow at a CAGR of 22.68% over the forecast period 2024-2032.
The Glioblastoma Multiforme Treatment Market size was valued at USD 2.69 billion in 2023 and is expected to reach at USD 5.68 billion by 2031 and grow at a CAGR of 9.8% over the forecast period of 2024-2031.
The Injection Pen Market was valued at USD 40.6 billion in 2023 and is projected to reach USD 73.8 billion by 2032, with a growing CAGR of 6.8% from 2024 to 2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
